期刊文献+

采用混合模式色谱与电雾式检测器测定蛋白药物中的聚山梨醇酯20 被引量:8

Quantitation of polysorbate 20 in protein solutions using mixed-mode chromatography and charged aerosol detector
原文传递
导出
摘要 目的:建立混合模式色谱和电雾式检测器测定蛋白药物中的聚山梨醇酯20的含量。方法:色谱柱为Oasis MAX(2.1mm×20 mm,30μm),柱温30℃,流动相A为2%(体积分数)甲酸的异丙醇溶液,流动相B为2%(体积分数)甲酸的水溶液,梯度洗脱,进样体积30μL;电雾式检测器,雾化室温度30℃,采样频率5 Hz。结果:聚山梨醇酯20的峰面积与浓度线性回归方程为Y=6.643X-0.0445(r=0.9994),线性范围为9.4~188.0 mg·mL-1;峰面积和保留时间的RSD分别为0.66%和0.04%;平均回收率为98.3%;方法定量限(S/N=10)为1.1 mg·mL-1。结论:该仪器分析方法重现性较好,样品检出限较低,可作为药物及制剂中聚山梨醇酯20的含量测定方法。 Objective :To develop a mixed -mode chromatography and charged aerosol detector(CAD) method for the quantitative determination of polysorbate 20 in protein pharmaceuticals. Methods:Oasis MAX column(2. 1 mm × 20 mm,30 μm) was used in the study and the column temperature was 30 ℃. The mobile phase was composed of iso- propanol containing 2 % (v/v) formic acid ] and water [ containing 2 % (v/v) formic acid ] with gradient elution ; the injection volume was 30 IxL;CAD:nebulization temperature was 30 ℃ and collection frequency was 5 Hz. Results: The equation of linear regression was Y = 6. 643X - 0. 0445 ( r = 0. 9994 ) , linear range was 9.4 - 188.0 mg· mL-1 ;the RSD value of peak area and retention time was 0. 66% and 0. 04%, respectively;the average recovery was 98.29% ;the LOQ( as S/N= 10) was 1.1 mg · mL-1. Conclusion:The established method is sensitive and ac- curate, which can be used in the quantitative determination of polysorbate 20 in protein pharmaceuticals.
出处 《药物分析杂志》 CAS CSCD 北大核心 2013年第3期465-469,共5页 Chinese Journal of Pharmaceutical Analysis
关键词 混合模式色谱 电雾式检测器 聚山梨醇酯20(吐温20) 蛋白药物 mixed - mode chromatography charged aerosol detector (CAD) polysorbate 20 ( Tween 20 ) protein pharmaceuticals
  • 相关文献

参考文献17

二级参考文献50

  • 1寇秀颖,于国萍.脂肪和脂肪酸甲酯化方法的研究[J].食品研究与开发,2005,26(2):46-47. 被引量:234
  • 2赵青蓉,余蓉.分光光度法检测S/D处理中纯因子Ⅷ制品中残留Tween-80方法研究[J].中国输血杂志,1996,9(3):122-124. 被引量:7
  • 3王庆利,彭健.吐温80的安全性研究进展[J].毒理学杂志,2006,20(4):262-264. 被引量:55
  • 4苏德森,王思玲.物理药利学[M].北京:化学工业出版社,2004:198.
  • 5陈振江.临界胶束浓度的测定与应用.中成药,1993,15(11):43-44.
  • 6霍姆博格 K,琼森 B,科隆博格B,林德曼B,(瑞典)著.韩丙勇,张学军译.水溶液中的表面活性剂和聚合物(原著第2版)[M].北京:化学工业出版社,2005:1.
  • 7Vlasak J,Ionescu R.Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods.Curr Pharm Biotechnol,2008,9:468.
  • 8Manning MC,Patal K,Borchardt RT.Stability of protein pharmaceuticals.Pharm Res 1989,6(11):903.
  • 9Han M,Guo A,Jochheim C,et al.Analysis of glycosylated type II interleukin-1 receptor (IL-1R) by imaged capillary isoelectric focusing(i-cIEF).Chromatographia,2007,66:969.
  • 10Douglass JV,Wallace A,Balland A.Saparation of populations of antibody variants by fine tuning of hydrophobic-interaction chromatography operating conditions.J Chromatogra A,2008,1214:81.

共引文献87

同被引文献112

  • 1国家药典委员会.中国药典2010年版[s].一部.北京:中国医药科技出版社,2010:158.
  • 2Ribera PE, Curran A. Current role of tenofovir in clinical medi- cine [ J ]. Enferm Infecc Microbiol Clin,2008,26 (Suppl 8 ) :45.
  • 3Novoa SR, Iabarga P, Sofiano V. Pharmacogenetics of tenofovir treatment[ J ]. Pharmacogenomics ,2009,10(10) : 1675.
  • 4Paredes R, Clotet B. Clinical management of HIV - 1 resistance [ J]. Antiviral Res ,2010,85 ( 1 ) :245.
  • 5DeChristoforo R, Penzak SR. Tenofovir: a nucleotide analogue re- verse - transcriptase inhibitor for treatment of HIV infection [ J ]. Am J Health Syst Pharm,2004 ,61 ( 1 ) :86.
  • 6Grim SA, Romanelli F. Tenofovir disoproxil fumarate [ J ]. Ann Pharmacother ,2003 ,37 ( 6 ) :849.
  • 7Fung HB, Stone EA, Piacenti FJ. Tenofovir disoproxil fumarate : a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection[ J]. Clin Ther ,2002 ,24 (10) : 1515.
  • 8Lanier ER, Ptak RG, Lampert BM, et al. Development of hexade- cyloxypropyl tenofovir (CMX 157 ) for treatment of infection caused by wild - type and nucleoside/nucleotide - resistant HIV [ J ]. Antimicrob Agents Chemother,2010,54 ( 7 ) :2901.
  • 9姜庆伟,杨瑞,梅兴国.HPLC-电雾式检测器(CAD)检测法测定脂质体中磷脂含量[J].中国药学杂志,2007,42(23):1794-1796. 被引量:10
  • 10BAI J,SUN Q,ZHAI H. A comparison of oxytocin and carboprost tromethamine in the prevention of postpartum hemorrhage in high- risk patients undergoing cesarean delivery [ J ]. Exp Ther Med, 2014,7(1) :46 -50.

引证文献8

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部